Micron Biomedical, who develop dissolvable, microarray-based products to simplify the delivery of drugs and vaccines, have announced that they have added $3m to its Series A, bringing the total funding to $17m.
Micron said its Series A extension further supports efforts to bring its drug delivery technology to market. It said its focus centers around national health security and meeting needs of underserved populations. Its patented microarray technology enables the administration of drugs and vaccines that require cold storage and administration within minutes. It can be self-administered or caregiver-administered. The technology simplifies transport, storage and administration while eliminating traditional injection sharps waste. Completed trials demonstrated clinical efficacy and strong patient preference, according to the company.
To read more, CLICK HERE.